Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview
In8Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative gamma-delta T cell immunotherapies for cancer treatment. Utilizing state-of-the-art approaches such as allogeneic, autologous, and genetically modified T cells, the company is at the forefront of applying advanced immunology in the fight against both solid and hematologic malignancies. By leveraging its robust DeltEx platform, In8Bio is pioneering the integration of cell-based therapies into standard clinical protocols, a subject of high relevance in the fields of oncology and immunotherapy.
Clinical Programs and Technological Innovation
The company is deeply engaged in multiple clinical programs that advance its gamma-delta T cell product candidates into various stages of clinical investigation. Its innovative approach harnesses the unique ability of gamma-delta T cells to recognize and destroy cancer cells while differentiating between healthy and diseased tissues. The immunotherapies developed by In8Bio are designed to overcome current challenges in cancer treatment by demonstrating resilience in the presence of conventional modalities such as chemotherapy. This novel methodology indicates a significant step forward in addressing persistent gaps in progression-free survival for patients afflicted with difficult-to-treat cancers.
Pipeline and Portfolio
In8Bio maintains a diverse portfolio of cell therapy candidates that target both solid tumors, such as aggressive brain cancers, and liquid tumors, including high-risk hematologic malignancies. The company emphasizes the potential of its genetically modified gamma-delta T cells which are engineered to be chemotherapy-resistant, thereby enabling their effective use in combination with standard-of-care treatments. Its strategic portfolio reflects a deliberate focus on creating therapies that provide robust antitumor activity with a favorable safety profile, which is crucial in clinical settings.
Market Position and Competitive Landscape
Operating within a competitive and dynamic segment of the biotechnology and oncology markets, In8Bio distinguishes itself by being one of the first companies to translate genetically modified gamma-delta T cell therapy into clinical studies. The company’s efforts to integrate advanced cell therapy with conventional cancer management protocols underscore its role as a pioneer in the immunotherapy space. Its scientific and clinical strategies are rooted in extensive research, aiming to expand treatment options for patients with unmet medical needs while setting a benchmark for future research in cell-based therapies.
Research and Development Focus
The core of In8Bio’s business model lies in its commitment to rigorous research and clinical validation. The company employs a systematic approach to clinical investigation, ensuring that its product candidates are evaluated through well-designed studies. This commitment to science and robust clinical trial methodologies not only enhances the credibility of its findings but also contributes to the broader scientific understanding of gamma-delta T cell functions in oncology. The integration of innovative technologies with traditional treatment regimens speaks to the company’s strategy of enhancing therapeutic durability and safety.
Operational Excellence and Strategic Vision
In8Bio is characterized by its deep commitment to scientific excellence and operational transparency. Its research pipeline is supported by meticulous clinical studies that investigate both short-term efficacy and long-term safety profiles of its cell therapies. By positioning its programs at the interface of immunology and oncology, the company provides a pertinent example of how novel biotechnology can offer alternative options for cancer patients. This blend of advanced immunotherapeutic strategies and rigorous clinical science reinforces In8Bio’s reputation as a credible and knowledgeable entity in the biopharmaceutical landscape.
Investor Insights and Frequently Asked Questions
Investors and industry researchers looking into In8Bio will find that the company’s emphasis on gamma-delta T cell therapies offers a unique intersection of cellular immunotherapy and targeted cancer treatments. The detailed clinical programs, alongside strategic R&D initiatives, provide ample context on the company’s approach to addressing unmet needs in oncology. By maintaining a balanced perspective on both the promise and challenges inherent in advanced cell therapies, In8Bio continues to contribute to the evolution of cancer treatment paradigms with ongoing scientific rigor and clinical evaluation.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, announced that CEO and co-founder William Ho will present at NobleCon20 on December 3, 2024, at 10:30 am ET. The presentation will be available through a high-definition video webcast on the company's investor relations website, Noble Capital Markets' Conference website, and Channelchek platform. The webcast recording will remain accessible for 90 days after the event on all three platforms.
IN8bio presented results from their fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. 50% of patients receiving repeated doses (n=10) remained alive and in remission beyond expected median overall survival, while single-dose patients (n=3) did not achieve this outcome. The trial demonstrated that 92% of evaluable patients surpassed median standard-of-care progression-free survival (PFS) of 6.9 months. Notably, multi-dose cohorts showed improved peripheral T cell recovery, with one patient remaining progression-free at 40.5 months. Biopsy results confirmed gamma-delta T cell presence in the brain tumor microenvironment. The treatment showed no serious adverse events, with most common side effects being Grade 1-2 toxicities.
IN8bio (NASDAQ: INAB) reported Q3 2024 financial results and corporate updates. The company reported that 100% of Acute Myeloid Leukemia patients treated with INB-100 remain in complete remission. The INB-100 trial is expanding enrollment to approximately 25 patients. Financial highlights include R&D expenses of $3.3 million (down from $3.8 million YoY), G&A expenses of $2.7 million (down from $3.4 million YoY), and a net loss of $7.1 million ($0.15 per share). The company secured $11.6 million through a private placement in October 2024, extending cash runway through 2025.
IN8bio (Nasdaq: INAB) announced an upcoming plenary oral presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2024. The presentation will provide extended follow-up data from the Phase 1 trial of INB-200, their gamma-delta T cell therapy for newly diagnosed glioblastoma.
Previous data presented at ASCO in June 2024 showed that 92% of evaluable patients exceeded the median progression-free survival of 7 months typically observed with standard-of-care therapy. The presentation will be delivered by Dr. Mina Lobbous from Cleveland Clinic Lerner College of Medicine.
IN8bio (Nasdaq: INAB) has announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentation will focus on INB-100, a pilot study of donor-derived gamma-delta T cell therapy following haploidentical hematopoietic stem-cell transplantation. Dr. Joseph McGuirk from The University of Kansas Cancer Center will present Abstract #4823 in the Cellular Immunotherapies session on December 9, 2024, from 6:00 PM to 8:00 PM PDT. The abstract will be available online through ASH's website, with poster reprints accessible on IN8bio's website after the presentation.
IN8bio, Inc. (Nasdaq: INAB) has announced a $12.4 million private placement to fund its current operating plan into 2026. The financing will support the ongoing expansion cohorts in the Phase 1 trial of INB-100 for patients with Acute Myeloid Leukemia (AML). The private placement includes the sale of 25,759,595 shares of common stock, pre-funded warrants for 5,646,853 shares, and warrants to purchase up to 31,406,448 shares.
The proceeds will enable IN8bio to increase enrollment to approximately 25 patients in the expansion cohort at the recommended Phase 2 dose, with completion expected in the first half of 2025. Long-term follow-up results are anticipated in late 2025 and 2026. The company also plans to add a parallel control cohort to assess leukemia patients and compare INB-100 treatment to standard haplotransplantation.
IN8bio (Nasdaq: INAB) has announced a strategic pipeline prioritization and workforce reduction to optimize resource allocation. The company will focus on its INB-100 program for Acute Myeloid Leukemia (AML), which has shown promising results with 100% progression-free survival as of August 30, 2024. IN8bio will suspend enrollment in its Phase 2 clinical trial of INB-400 for glioblastoma (GBM) while continuing to monitor patients in both INB-400 and INB-200 trials.
The company plans to reduce its workforce by 49% and implement cash compensation reductions for executives and board members. These measures are expected to result in clinical cost savings and help preserve cash resources. IN8bio aims to complete additional enrollment for the INB-100 trial in the first half of 2025, with long-term follow-up results anticipated in late 2025 and 2026.
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. William Ho, CEO and co-founder of IN8bio, will be presenting in a fireside chat format on Monday, September 9, 2024, at 2:30 p.m. ET.
The presentation will be accessible via a live webcast, with a replay option available afterwards. Interested parties can find the webcast under the "Events and Presentations" section of the IN8bio website at https://investors.in8bio.com. This event provides an opportunity for investors and analysts to gain insights into IN8bio's innovative approach to cancer treatment using gamma-delta T cell therapies.
IN8bio (Nasdaq: INAB) has solidified its position as a clinical leader in gamma-delta T cell therapy for oncology. The company reported 100% of treated acute myeloid leukemia (AML) patients remain in complete remission. IN8bio received FDA guidance for a registrational trial of INB-100, with IND submission anticipated in Q1 2025. Early clinical data shows prolonged relapse-free survival in both AML and glioblastoma (GBM) programs, surpassing current standard-of-care. Both programs are advancing to Phase 2 clinical development. The company is the first to report improvements in relapse-free survival in both solid and hematological cancers using allogeneic or autologous gamma-delta T cells.
IN8bio (NASDAQ: INAB) reported Q2 2024 financial results and corporate highlights. Key points include:
1. Presented 100% 1-year complete remission in evaluable patients with hematologic malignancies for INB-100 at EHA 2024.
2. Demonstrated 92% of glioblastoma patients treated with INB-200 exceeded median seven-month progression-free survival at ASCO 2024.
3. Showcased robust manufacturing platform for DeltEx gamma-delta T cells at ASGCT 2024.
4. Q2 2024 financials: R&D expenses increased to $5.2 million, net loss was $8.6 million ($0.19 per share), and cash position as of June 30, 2024, was $10.2 million.
IN8bio continues to advance its gamma-delta T cell therapies for solid and hematologic cancers, showing promising results in clinical trials.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is the primary focus of In8Bio, Inc.?
How does In8Bio approach cancer treatment differently?
Which types of cancers does In8Bio target?
What makes the company’s technology innovative?
How does In8Bio ensure the safety of its therapies?
In what stage of development is In8Bio’s therapy pipeline?
How does In8Bio differentiate itself from other biopharmaceutical companies?
What benefits do gamma-delta T cells offer in cancer treatment?
